Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 4 × OTHER_GOV × Nadolol × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Liver Cirrhosis 1 Carcinoma, Hepatocellular 1

Interventions

human papillomavirus vaccine, L1 type 16, 18 3 Propranolol 3 entecavir 2 Tranexamic Acid 2 Radiotherapy 2 Pemetrexed 2 Metformin 2 Erythromycin 2 Epinephrine 2 Cyclophosphamide 2 Cisplatin 2 Chemoradiotherapy 2 Bortezomib 2 ulipristal acetate 1 tislelizumab 1 plerixafor 1 ledipasvir 1 eribulin 1 endostar protein 1 dolutegravir 1 colistinmethanesulfonic acid 1 cetrorelix 1 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 1 XELOX 1 Vancomycin 1 Vacuum Curettage 1 Vaccination 1 Suction 1 Sofosbuvir 1 Sodium Chloride 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00567216 2010-06-08

GVO-nadolol

Taipei Veterans General Hospital, Taiwan

Phase 4 Unknown

Gastrointestinal

Carcinoma, Hepatocellular, Liver Cirrhosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡